Zealand Pharma AS (STU:22Z) EPS (Basic): €12.13 (TTM As of Mar. 2026)


STU:22Z Zealand Pharma AS STU:22Z
52 GF Score
Price €38.10
GF Value €1,718.98
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS EPS (Basic)?

Zealand Pharma AS STU:22Z +0.71% 52 EPS (Basic) is €12.13 as of Mar. 2026. GuruFocus rates STU:22Z with a GF Score™ of 52/100 and a GF Value™ of €1,718.98 (Possible Value Trap). The stock has 3 warning signs investors should review.

Zealand Pharma AS's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.75. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €12.13.

Zealand Pharma AS's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.75. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €11.93.

Zealand Pharma AS's EPS without NRI for the three months ended in Mar. 2026 was €-0.76. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 12.16.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Zealand Pharma AS's highest 3-Year average EPS without NRI Growth Rate was 16.80% per year. The lowest was -61.20% per year. And the median was -10.80% per year.

Zealand Pharma AS  (STU:22Z) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Zealand Pharma AS EPS (Basic) Related Terms

Zealand Pharma AS EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS EPS (Basic) Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.19 -3.50 -1.67 -2.18 12.26

Zealand Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 14.35 -0.77 -0.71 -0.75
STU:22Z
52GF Score
Zealand Pharma AS STU:22Z
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Zealand Pharma AS's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(864.257-0)/70.501
=12.26

Zealand Pharma AS's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-52.714-0)/70.609
=-0.75

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €12.13 mean?
Zealand Pharma AS (STU:22Z) has a EPS (Basic) of €12.13 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's EPS (Basic) too high?
Zealand Pharma AS's current EPS (Basic) is €12.13. Overall, Zealand Pharma AS has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's EPS (Basic) compare to VRTX and REGN?
Zealand Pharma AS's EPS (Basic) of €12.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current EPS (Basic) is €12.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (STU:22Z) is currently considered Possible Value Trap. The stock's GF Value™ is €1,718.98, compared to a current price of €38.10 — trading 97.8% below its estimated fair value. The current EPS (Basic) is €12.13. Zealand Pharma AS's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Zealand Pharma AS (STU:22Z), the current EPS (Basic) is €12.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (STU:22Z) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of €38.10 is trading 97.8% below its estimated GF Value™ of €1,718.98. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for STU:22Z:

  • EPS (Basic): €12.13
  • GF Value™: €1,718.98 vs. price of €38.10 (97.8% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the STU:22Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
52GF Score

Get the complete analysis for STU:22Z

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.10
Price
€1,718.98
GF Value